Duchenne muscular dystrophy is a devastating inherited neuromuscular disorder that affects
one in 3300 live male births. Although the responsible gene and its product, dystrophin …

Myostatin, which was cloned in 1997, is a potent inhibitor of skeletal muscle growth and
member of the tumour growth factor-β family. Disruption of the myostatin gene in mice …

The lack of myostatin promotes growth of skeletal muscle, and blockade of its activity has
been proposed as a treatment for various muscle-wasting disorders. Here, we have …

Myostatin is a transforming growth factor-ß family member that normally acts to limit skeletal
muscle growth. Mice genetically engineered to lack myostatin activity have about twice the …

Dystrophic muscle disease can occur at any age. Early-or childhood-onset muscular
dystrophies may be associated with profound loss of muscle function, affecting ambulation …

Muscle wasting and weakness are common in many disease states and conditions including
aging, cancer cachexia, sepsis, denervation, disuse, inactivity, burns, HIV-acquired …

Myostatin is an endogenous, negative regulator of muscle growth determining both muscle
fiber number and size. The myostatin pathway is conserved across diverse species ranging …

Constitutive myostatin gene knockout in mice causes excessive muscle growth during
development. To examine the effect of knocking out the myostatin gene after muscle has …

Myostatin is a negative regulator of muscle mass whose inhibition has been proposed as a
therapeutic strategy for muscle-wasting conditions. Indeed, blocking myostatin action …

A number of recent studies have demonstrated therapeutic effects of transgenes on the
development of muscle pathology in the mdx mouse model for Duchenne muscular …